3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
4
Completed
4
Recruiting
3
Active not recruiting
3
Withdrawn
1
Not yet recruiting
1
Available
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Hepatocellular
2
Pancreatic Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma
1
Interventions
pembrolizumab
6
avelumab
4
Magnetic Resonance Spectroscopy
2
Docetaxel
2
Cisplatin
2
ALT-803
2
yeast-CEA vaccine
1
vadimezan
1
trebananib
1
obinutuzumab
1
naptumomab estafenatox
1
erdafitinib
1
enfortumab vedotin
1
bicalutamide
1
atezolizumab
1
Ultrasonography
1
Specimen Handling
1
Ramucirumab
1
Radiosurgery
1
Phantoms, Imaging
1
PM 01183
1
Omacor
1
Nivolumab
1
Neoadjuvant Therapy
1
Mitomycin
1
Lycopene
1
Leucovorin
1
High-Intensity Focused Ultrasound Ablation
1
Gemcitabine
1
Fulvestrant
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Carcinoma, Transitional Cell
×
Mitomycin
×
Clear all
NCT04006691
2020-05-07
Retreatment
UroGen Pharma Ltd.
Phase 3
Withdrawn